 Pharmacogenetics
"Pharmacogenetics" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A branch of genetics which deals with the genetic variability in individual responses to drugs and drug metabolism (BIOTRANSFORMATION).
| Descriptor ID |
D010597
|
| MeSH Number(s) |
H01.158.273.343.750 H01.158.703.052 H02.628.479
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenetics".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenetics".
This graph shows the total number of publications written about "Pharmacogenetics" by people in this website by year, and whether "Pharmacogenetics" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 1 | 0 | 1 | | 2007 | 1 | 3 | 4 | | 2008 | 1 | 2 | 3 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 0 | 2 | 2 | | 2012 | 1 | 3 | 4 | | 2014 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pharmacogenetics" by people in Profiles.
-
Mahmoud M, Mason KP. A forecast of relevant pediatric sedation trends. Curr Opin Anaesthesiol. 2016 Mar; 29 Suppl 1:S56-67.
-
Pappas DA, Kremer JM, Reed G, Greenberg JD, Curtis JR. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients". BMC Musculoskelet Disord. 2014 Apr 01; 15:113.
-
Roses AD, Saunders AM, Lutz MW, Zhang N, Hariri AR, Asin KE, Crenshaw DG, Budur K, Burns DK, Brannan SK. New applications of disease genetics and pharmacogenetics to drug development. Curr Opin Pharmacol. 2014 Feb; 14:81-9.
-
Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G. The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-a antagonist therapies. Clin Exp Rheumatol. 2013 Mar-Apr; 31(2):189-94.
-
Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55.
-
Fuster V, Bhatt DL, Califf RM, Michelson AD, Sabatine MS, Angiolillo DJ, Bates ER, Cohen DJ, Coller BS, Furie B, Hulot JS, Mann KG, Mega JL, Musunuru K, O'Donnell CJ, Price MJ, Schneider DJ, Simon DI, Weitz JI, Williams MS, Hoots WK, Rosenberg YD, Hasan AA. Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation. 2012 Sep 25; 126(13):1645-62.
-
Rosen Y, Upadhyay UM, Elman NM. Pharmacogenomics-based RNA interference nanodelivery: focus on solid malignant tumors. Expert Opin Drug Deliv. 2012 Jul; 9(7):755-66.
-
Stanek EJ, Sanders CL, Taber KA, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012 Mar; 91(3):450-8.
-
Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23; 306(20):2221-8.
-
Shaughnessy JD, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011 Sep 29; 118(13):3512-24.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|